Immunome, Inc.(IMNM)

$29.82—

Chart

Immunome, Inc.(IMNM)

NASDAQ

$29.82—

Chart Studio

IMNM(IMNM)

IMNM

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.61

Nov 5, 2026

Revenue Estimate

$166,667

FY2030E EPS$1.16

Analyst Sentiment

Wall St. Consensus

Buy

13 analysts·Moderate coverage

Score

13 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

13100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$33.00

+10.6%

Consensus

$35.50

+19.0%

Bull

$37.00

+24.1%

12-Month Target Range13 analysts

$33.00$35.50$37.00

Current $29.82Consensus

Current Price

$29.82

Upside to Consensus

$5.68

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+10223.11%

EPS—

FY2028

Rev+299.21%

EPS—

FY2029

Rev+79.23%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$545,455	$56M	$225M	$403M	$613M
Low	$162,458	$18M	$75M	$120M	$183M
High	$922,767	$111M	$330M	$682M	$1.04B
EBITDA Avg	$-109,090	$-11M	$-45M	$-81M	$-123M
Low	$-184,553	$-22M	$-66M	$-136M	$-207M
High	$-32,491	$-4M	$-15M	$-24M	$-37M
EBIT Avg	$-109,090	$-11M	$-45M	$-81M	$-123M
Low	$-184,553	$-22M	$-66M	$-136M	$-207M
High	$-32,491	$-4M	$-15M	$-24M	$-37M
Net Income Avg	$-188M	$-189M	$-106M	$-7M	$101M
Low	$-195M	$-222M	$-198M	$-14M	$9M
High	$-181M	$-157M	$-35M	$-631,065	$192M
EPS Avg	$-2.14	$-2.18	$-1.13	$-0.08	$1.16
Low	$-2.24	$-2.55	$-2.27	$-0.16	$0.10
High	$-2.07	$-1.79	$-0.40	$-0.01	$2.19
Analysts (Rev / EPS)	8 / 10	8 / 9	9 / 8	4 / 5	4 / 5

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$166,667	$181,818	$5M	$9M	$18M	$26M
Low	$166,667	$174,244	$5M	$9M	$18M	$26M
High	$166,667	$189,392	$5M	$9M	$18M	$26M
EBITDA Avg	$-33,333	$-36,363	$-942,857	$-2M	$-4M	$-5M
Low	$-33,333	$-37,878	$-942,857	$-2M	$-4M	$-5M
High	$-33,333	$-34,848	$-942,857	$-2M	$-4M	$-5M
EBIT Avg	$-33,333	$-36,363	$-942,857	$-2M	$-4M	$-5M
Low	$-33,333	$-37,878	$-942,857	$-2M	$-4M	$-5M
High	$-33,333	$-34,848	$-942,857	$-2M	$-4M	$-5M
Net Income Avg	$-63M	$-67M	$-67M	$-61M	$-58M	$-64M
Low	$-67M	$-82M	$-67M	$-61M	$-58M	$-64M
High	$-61M	$-41M	$-67M	$-61M	$-58M	$-64M
EPS Avg	$-0.56	$-0.59	$-0.59	$-0.54	$-0.51	$-0.57
Low	$-0.59	$-0.72	$-0.59	$-0.54	$-0.51	$-0.57
High	$-0.54	$-0.36	$-0.59	$-0.54	$-0.51	$-0.57
Analysts (Rev / EPS)	6 / 9	12 / 13	6 / 5	6 / 5	6 / 5	6 / 5

Earnings Surprises

Recent Analyst Actions

Aug 12, 2026Wedbush

Immunome price target raised to $35 from $31 at Wedbush

Target:$35.00

+33.2%from $26.27

May 28, 2026Truist Financial

Immunome Inc. (IMNM) PT Raised to $37 at Truist Securities, Assumes Coverage

Target:$37.00

+67.3%from $22.11

May 28, 2026Barclays

Barclays Starts Immunome Inc. (IMNM) at Overweight

Target:$36.00

+62.8%from $22.11

May 15, 2026Leerink Partners

Immunome price target lowered to $33 from $37 at Leerink

Target:$33.00

+49.9%from $22.02

Feb 12, 2026H.C. Wainwright

Immunome initiated with a Buy at H.C. Wainwright

Target:$40.00

+70.9%from $23.41

Dec 16, 2025Lake Street

Immunome price target raised to $32 from $22 at Lake Street

Target:$32.00

+36.8%from $23.39

Dec 16, 2025Evercore ISI

Immunome price target raised to $40 from $18 at Evercore ISI

Target:$40.00

+71.3%from $23.35

Dec 15, 2025Leerink Partners

Immunome price target raised to $40 from $38 at Leerink

Target:$40.00

+76.6%from $22.65

Dec 1, 2025Truist Financial

Immunome initiated with a Buy at Truist

Target:$36.00

+95.4%from $18.42

Nov 17, 2025Stephens

Immunome Inc. (IMNM) PT Raised to $33 at StephensMember Login

Target:$33.00

+92.5%from $17.14

Sep 5, 2025Craig-Hallum

Immunome initiated with a Buy at Craig-Hallum

Target:$26.00

+147.1%from $10.52

Aug 22, 2025Evercore ISI

Immunome initiated with an Outperform at Evercore ISI

Target:$18.00

+74.8%from $10.30

Aug 13, 2024Piper Sandler

Immunome price target lowered to $23 from $27 at Piper Sandler

Target:$23.00

+82.0%from $12.64

Apr 15, 2024Guggenheim

Immunome initiated with a Buy at Guggenheim

Target:$35.00

+70.1%from $20.58

Apr 1, 2024Wedbush

Immunome price target raised to $33 from $27 at Wedbush

Target:$33.00

+33.7%from $24.68

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance